Life Insurance (LICI)

FairStock Score: 86/100 — HIGH CONVICTION

Score breakdown: P/E: 3/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Investment Thesis

LICI is a government-owned life insurance stalwart with exceptional profitability (ROE 37.34%, ROCE 53.13%), near-zero debt, and a current P/E of 8.7 against 40% YoY profit growth. The latest price of ₹413.5 is well below the Graham number of ₹650.58, but the quant package is mixed: earnings momentum is bullish while volume anomaly and imbalance are bearish, and several signals appear stale at ₹811.9. I view this as a fundamentally cheap, high-quality franchise that requires patience because low free float and weak near-term volume create execution risk.

Rating: BUY (MEDIUM confidence) — 12M horizon

Strengths

• Government-owned market leader with 96.5% promoter holding and a trusted franchise in Indian life insurance.
• Exceptional profitability: ROE of 37.34% and ROCE of 53.13% with near-zero debt.
• Current P/E of 8.7 with 40% YoY profit growth is very attractive; at ₹413.5 the stock is about 36% below the Graham number of ₹650.58.
• Strong free cash flow of ₹31,687 crore and a dividend yield of 2.42%.
• FairStock Score of 7/10 (Steady) and Stalwart category.

Concerns

• Top-line growth is modest at 6.8% YoY; this is not a fast-growth business.
• Extremely low float creates high market impact: a ₹1 crore trade can move price by about 52.7 bps.
• Volume anomaly ratio of 0.024 is very low and the 5-day volume imbalance is -41.8%, indicating weak buying interest.
• The stock remains 56% below its 52-week high of ₹936.95; the downtrend is not yet technically repaired.
• Some quant signals (mean reversion, price-value) are stale at ₹811.9, so the current picture needs fresh confirmation.

AI Analysis

Here is what you need to know about LICI. LIC India is a government-owned life insurance giant, and right now the stock trades around ₹413.5 with a price-to-earnings ratio of just 8.7. The company earns a return on equity above 37% and a return on capital employed above 53%. It has virtually no debt, pays a dividend of about 2.4%, and last year's profit grew by 40%. On paper, that is a very cheap, high-quality stalwart. But the market is not giving it much respect. The stock has fallen from a 52-week high of ₹936 to around ₹413, and daily volume has dried up dramatically. One recent day saw only about 36,500 shares trade, compared with a 20-day average of over 1.5 million. My volume anomaly signal flags that as a strong sell because it shows big institutions are not stepping in to support the stock. The five-day volume imbalance is also negative, meaning there has been more selling pressure than buying pressure recently. The mean-reversion model gives a z-score of negative 0.74, which is basically neutral—it is not stretched enough to suggest a sharp bounce. I should also mention that some of these quant signals were calculated when the stock was around ₹811, so they are stale. At today's price, the stock is actually below its Graham number of about ₹650, which gives long-term value investors a margin of safety. But I do not have a fresh Hurst exponent or variance ratio to confirm the mean-reversion regime, so I do not want to overstate the timing. In plain language, this is a high-quality, government-backed insurer trading at very low earnings multiples, but it has a very small public float—only about three and a half percent of shares are freely traded. That means even a ₹1 crore order can move the price by more than half a percent, and large investors may struggle to enter or exit without pushing the price around. The short-term setup looks rangebound between roughly ₹408 and ₹425. A break above ₹425 on strong volume would be the first sign that demand is returning. For a retail investor, I would treat this as a long-term value opportunity, not a momentum trade. My recommendation is a cautious BUY for a 12-month horizon, but keep the initial position small—around two to four percent of your equity—and wait for volume to improve before adding. Patience is essential.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer